阿托伐他汀与食管癌风险降低相关：来自中国台湾的一项基于人群的病例对照研究。
Atorvastatin correlates with decreased risk of esophageal cancer: a population-based case-control study from Taiwan.
机构信息
School of Medicine, China Medical University, Taichung, Taiwan.
出版信息
Libyan J Med. 2012;7. doi: 10.3402/ljm.v7i0.18830. Epub 2012 Aug 9.
OBJECTIVES
The aim of this study was to explore the association between the use of statins and esophageal cancer in Taiwan.
METHODS
We designed a case-control study using database from the Taiwan National Health Insurance program. In all, 549 patients (cases) aged 20 years or older diagnosed recently with esophageal cancer, from 2000 to 2009, and 2,196 subjects (controls) without esophageal cancer participated in this study. The association between esophageal cancer and the use of statins and other co-morbidities was measured.
RESULTS
After adjustment for covariates, multivariate logistic regression showed that patients with a cumulative duration of ≥ 12 months of using atorvastatin might have a reduced risk of esophageal cancer, compared with those who did not use statins (odds ratio [OR] 0.14, 95% confidence interval [CI] 0.04-0.56). The other statins could not show a significant association with esophageal cancer. Age (OR 1.01, 95% CI 1.00-1.01), alcoholism (OR 3.83, 95% CI 3.01-4.89), and esophageal diseases (OR 4.60, 95% CI 3.46-6.12) were independent factors significantly associated with esophageal cancer.
CONCLUSIONS
Use of atorvastatin ≥ 12 months may correlate with an 86% reduction of esophageal cancer risk.
目的
本研究旨在探讨台湾地区使用他汀类药物与食管癌之间的关联。
方法
我们采用来自台湾全民健康保险计划数据库的病例对照研究设计。总共纳入了 20 岁及以上、2000 年至 2009 年期间新近诊断为食管癌的 549 名患者（病例）和 2196 名无食管癌的对照者。测量了食管癌与他汀类药物使用及其他合并症之间的关联。
结果
经调整混杂因素后，多变量逻辑回归显示，与未使用他汀类药物者相比，累积使用阿托伐他汀 ≥ 12 个月的患者食管癌发病风险可能降低（比值比 [OR] 0.14，95%置信区间 [CI] 0.04-0.56）。其他他汀类药物与食管癌之间无显著相关性。年龄（OR 1.01，95% CI 1.00-1.01）、酗酒（OR 3.83，95% CI 3.01-4.89）和食管疾病（OR 4.60，95% CI 3.46-6.12）是与食管癌显著相关的独立因素。
结论
使用阿托伐他汀 ≥ 12 个月可能与食管癌风险降低 86%相关。
Zotero 插件